Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1962 2
1963 278
1964 425
1965 327
1966 331
1967 418
1968 476
1969 630
1970 692
1971 772
1972 852
1973 822
1974 1020
1975 860
1976 1012
1977 916
1978 1175
1979 1218
1980 1253
1981 1303
1982 1315
1983 1663
1984 1910
1985 1953
1986 2080
1987 3068
1988 4844
1989 5635
1990 6202
1991 6299
1992 6669
1993 7166
1994 7898
1995 7693
1996 8510
1997 8724
1998 8623
1999 8871
2000 10035
2001 10498
2002 11012
2003 12257
2004 12777
2005 13332
2006 13736
2007 14640
2008 14596
2009 14799
2010 16005
2011 17201
2012 18209
2013 19261
2014 20648
2015 21067
2016 21575
2017 21537
2018 20406
2019 19921
2020 22702
2021 23907
2022 23344
2023 22579
2024 6651

Text availability

Article attribute

Article type

Publication date

Search Results

494,117 results

Results by year

Filters applied: . Clear all
Page 1
Vasculogenic mimicry in carcinogenesis and clinical applications.
Luo Q, Wang J, Zhao W, Peng Z, Liu X, Li B, Zhang H, Shan B, Zhang C, Duan C. Luo Q, et al. J Hematol Oncol. 2020 Mar 14;13(1):19. doi: 10.1186/s13045-020-00858-6. J Hematol Oncol. 2020. PMID: 32169087 Free PMC article. Review.
VM is associated with high tumor grade, tumor progression, invasion, metastasis, and poor prognosis in patients with malignant tumors. Herein, we discuss the recent studies on the role of VM in tumor progression and the diverse mechanisms and signaling pathways that regula …
VM is associated with high tumor grade, tumor progression, invasion, metastasis, and poor prognosis in patients with malignant tumors …
The role of m6A RNA methylation in cancer metabolism.
An Y, Duan H. An Y, et al. Mol Cancer. 2022 Jan 12;21(1):14. doi: 10.1186/s12943-022-01500-4. Mol Cancer. 2022. PMID: 35022030 Free PMC article. Review.
Metabolic reprogramming is one of the main characteristics of malignant tumors, which is due to the flexible changes of cell metabolism that can meet the needs of cell growth and maintain the homeostasis of tissue environments. Cancer cells can obtain metabolic adaptation …
Metabolic reprogramming is one of the main characteristics of malignant tumors, which is due to the flexible changes of cell metaboli …
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading.
Christofer Juhlin C, Mete O, Baloch ZW. Christofer Juhlin C, et al. Endocr Relat Cancer. 2022 Dec 22;30(2):e220293. doi: 10.1530/ERC-22-0293. Print 2023 Feb 1. Endocr Relat Cancer. 2022. PMID: 36445235 Review.
The heterogeneous group of non-neoplastic and benign neoplastic lesions are now collectively termed as 'thyroid follicular nodular disease' to better reflect the clonal and non-clonal proliferations that clinically present as multinodular goiter. Thyroid n …
The heterogeneous group of non-neoplastic and benign neoplastic lesions are now collectively termed as 'thyroid follicular nod …
Pathology of gestational trophoblastic disease (GTD).
Kaur B. Kaur B. Best Pract Res Clin Obstet Gynaecol. 2021 Jul;74:3-28. doi: 10.1016/j.bpobgyn.2021.02.005. Epub 2021 Mar 31. Best Pract Res Clin Obstet Gynaecol. 2021. PMID: 34219021 Review.
Gestational trophoblastic disease (GTD) is subclassified into hydatidiform mole (HM), gestational trophoblastic tumours (GTT) and non-neoplastic trophoblastic lesions. ...GTT have a favourable prognosis and better response to specific chemotherapeutic regimens when …
Gestational trophoblastic disease (GTD) is subclassified into hydatidiform mole (HM), gestational trophoblastic tumours (GTT) and non …
Cancer progression and the invisible phase of metastatic colonization.
Klein CA. Klein CA. Nat Rev Cancer. 2020 Nov;20(11):681-694. doi: 10.1038/s41568-020-00300-6. Epub 2020 Oct 6. Nat Rev Cancer. 2020. PMID: 33024261 Review.
Metastatic dissemination occurs very early in the malignant progression of a cancer but the clinical manifestation of metastases often takes years. In recent decades, 5-year survival of patients with many solid cancers has increased due to earlier detection, local disea …
Metastatic dissemination occurs very early in the malignant progression of a cancer but the clinical manifestation of metastases ofte …
Diagnosis and treatment of cervical cancer in pregnant women.
Beharee N, Shi Z, Wu D, Wang J. Beharee N, et al. Cancer Med. 2019 Sep;8(12):5425-5430. doi: 10.1002/cam4.2435. Epub 2019 Aug 6. Cancer Med. 2019. PMID: 31385452 Free PMC article. Review.
In recent years, the incidence of gynecological malignant tumors during pregnancy has increased, mainly due to the increased number of old age pregnancy. The most common gynecological malignant tumors in pregnancy are cervical cancer, accounting for 71.6%, followed …
In recent years, the incidence of gynecological malignant tumors during pregnancy has increased, mainly due to the increased number o …
Stem cell fate in cancer growth, progression and therapy resistance.
Lytle NK, Barber AG, Reya T. Lytle NK, et al. Nat Rev Cancer. 2018 Nov;18(11):669-680. doi: 10.1038/s41568-018-0056-x. Nat Rev Cancer. 2018. PMID: 30228301 Free PMC article. Review.
Although we have come a long way in our understanding of the signals that drive cancer growth, and how these signals can be targeted, effective control of this disease remains a key scientific and medical challenge. The therapy resistance and relapse that are commonly seen …
Although we have come a long way in our understanding of the signals that drive cancer growth, and how these signals can be targeted, effect …
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel.
Yuan S, Almagro J, Fuchs E. Yuan S, et al. Nat Rev Cancer. 2024 Apr;24(4):274-286. doi: 10.1038/s41568-023-00660-9. Epub 2024 Feb 12. Nat Rev Cancer. 2024. PMID: 38347101 Review.
Cancer has long been viewed as a genetic disease of cumulative mutations. This notion is fuelled by studies showing that ageing tissues are often riddled with clones of complex oncogenic backgrounds coexisting in seeming harmony with their normal tissue counterparts. ...Co …
Cancer has long been viewed as a genetic disease of cumulative mutations. This notion is fuelled by studies showing that ageing tissu …
Cancer-related inflammation.
Candido J, Hagemann T. Candido J, et al. J Clin Immunol. 2013 Jan;33 Suppl 1:S79-84. doi: 10.1007/s10875-012-9847-0. Epub 2012 Dec 9. J Clin Immunol. 2013. PMID: 23225204 Review.
Solid tumors consist of neoplastic cells, non-malignant stromal cells, and migratory hematopoietic cells. ...MIF is a major cytokine in many cancers and there is evidence that the cytokine is produced by both malignant cells and infiltrating leukocytes. In th …
Solid tumors consist of neoplastic cells, non-malignant stromal cells, and migratory hematopoietic cells. ...MIF is a major cy …
Atypical fibroxanthoma.
Ziemer M. Ziemer M. J Dtsch Dermatol Ges. 2012 Aug;10(8):537-50. doi: 10.1111/j.1610-0387.2012.07980.x. Epub 2012 Jun 19. J Dtsch Dermatol Ges. 2012. PMID: 22709412 Free article. Review. English, German.
Atypical fibroxanthoma (AFX) is a rare neoplastic disease of the skin. Since the term was coined in the early 1960s, the disease has been viewed in many ways. For a long time AFX was regarded as a superficial variant of malignant fibrous histiocytoma ( …
Atypical fibroxanthoma (AFX) is a rare neoplastic disease of the skin. Since the term was coined in the early 1960s, the di …
494,117 results
You have reached the last available page of results. Please see the User Guide for more information.